These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12111113)

  • 1. Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
    Herben VM; Schoemaker nE; Rosing H; van Zomeren DM; ten Bokkel Huinink WW; Dubbelman R; Hearn S; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):59-64. PubMed ID: 12111113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral topotecan: bioavailablity and effect of food co-administration.
    Herben VM; Rosing H; ten Bokkel Huinink WW; van Zomeren DM; Batchelor D; Doyle E; Beusenberg FD; Beijnen JH; Schellens JH
    Br J Cancer; 1999 Jul; 80(9):1380-6. PubMed ID: 10424739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination pathways of [14C]losoxantrone in four cancer patients.
    Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
    Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
    Klein CE; Kastrissios H; Miller AA; Hollis D; Yu D; Rosner GL; Grinblatt DL; Larson RA; Ratain MJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):199-206. PubMed ID: 16158312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design.
    Saghir SA; Clark AJ; McClymont EL; Staley JL
    Food Chem Toxicol; 2008 Feb; 46(2):678-87. PubMed ID: 17961896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
    Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of oral topotecan in hematological malignancies.
    Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
    Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan lacks third space sequestration.
    Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
    Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
    Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
    Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
    Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.